Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Highlights

A collection of news and information related to Genentech Inc. published by this site and its partners.

Sort By: Relevancy | Date | Type
Displaying items 1-12 of 63
» View latimes.com items only
    May 18, 2013 |Story| McClatchy-Tribune
  1. BRIEF: Event features stroke information

    The Record, Stockton, Calif.
    Find out about the signs of stroke from 10 a.m. to 4 p.m. Thursday at the WorkNet Building, 56 S. Lincoln St. The event, sponsored by Stockton nonprofit Healings in Motion and Genentech, is free but requires an RSVP. It will include screenings for...

    Tags: Physical Conditions

  2. May 12, 2013 |Story| Los Angeles Times
  3. Bill would regulate 'biosimilar' drugs

    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs.
    SACRAMENTO — Two of the nation's largest biotech companies — Amgen Inc. of Thousand Oaks and Genentech Inc. of South San Francisco — are fighting in Sacramento to keep a tight grip on some of their most lucrative drugs. At stake is a...

    Tags: Pharmaceuticals, Food and Drug Administration, Health and Medical Professionals, Jerry Hill, Chemical Industry

  4. May 2, 2013 |Story| South Florida Sun-Sentinel
  5. International consortium releases hepatitis C data

    Two antiviral drugs used to treat hepatitis C appear to work as well in the real world as they did during clinical trials, an international research consortium has observed. The consortium also released data that may help inform how doctors and patients...

    Tags: Vertex Pharmaceuticals Incorporated, Health Organizations, Anemia, Research, Cirrhosis

  6. Apr 29, 2013 |Story| Allentown Morning Call
  7. Passenger on flight out of Philly detained for not flushing toilet

    PHILADELPHIA — A passenger who flew from Philadelphia to San Francisco was detained on arrival by federal agents after a vindictive flight attendant claimed he had not flushed a lavatory toilet, according to a federal suit. The suit, which seeks...

    Tags: FBI, Virgin Group, Ltd.

  8. Apr 25, 2013 |Story| Los Angeles Times
  9. HIV vaccine trial shut down

    In another major setback for efforts to develop an HIV vaccine, federal researchers have shut down a key clinical trial after an independent panel of safety experts determined that volunteers who got an experimental vaccine appeared to be slightly more...

    Tags: AIDS, Genetic Engineering, Disease Prevention, Allergies, Health Organizations

  10. Apr 24, 2013 |Story| Chicago Tribune
  11. Boeing, billionaire Penny Pritzker among Obama's donors

    Illinois donors to President Barack Obama’s second inauguration included aviation giant Boeing Co., which contributed $1 million, and billionaire Penny Pritzker, who gave $250,000, according to newly filed records.
    Tribune reporter
    Illinois donors to President Barack Obama’s second inauguration included aviation giant Boeing Co., which contributed $1 million, and billionaire Penny Pritzker, who gave $250,000, according to newly filed records. Pritzker, who is being vetted by...

    Tags: Human Interest, Engineering, Penny Pritzker, Gaming, Barack Obama

  12. Apr 22, 2013 |Story| Los Angeles Times
  13. Major corporations backed inaugural festivities

    WASHINGTON — President Obama's second inaugural committee raised a little more than $43 million to put on the official festivities surrounding his January swearing-in, backed by major donations from some of the country's biggest corporations,...

    Tags: International Association of Fire Fighters, Human Interest, Labor Legislation, Career and Workplace, Eli's Cheesecake Company

  14. Apr 19, 2013 |Story| Los Angeles Times
  15. Strategies for cutting the cost of prescription drugs

    When Maggie Heim had a recurrence of ovarian cancer about a year after her initial treatment, her oncologist suggested that she take what he believed could be a lifesaving drug. There was just one problem: Her insurer wouldn't pay for it.
    When Maggie Heim had a recurrence of ovarian cancer about a year after her initial treatment, her oncologist suggested that she take what he believed could be a lifesaving drug. There was just one problem: Her insurer wouldn't pay for it. The 59-year-...

    Tags: Cedars-Sinai Medical Center, Career and Workplace, Oncology, Herceptin (drug), Drugs and Medicines

  16. Mar 29, 2013 |Story| Los Angeles Times
  17. Remove Medicare's straitjacket

    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although raising the age of Medicare eligibility from 65 to 67 appears off the table, at least for now, the budget plan that Rep. Paul D. Ryan (R-Wis.) is proposing would shift a greater share of the program's growing costs to beneficiaries in the years to come.
    Now that the budget "sequester" is in effect, Congress is shifting its attention to entitlement reform. There's simply no way to achieve long-term reductions in federal spending without touching the big health programs, particularly Medicare. Although...

    Tags: Food and Drug Administration, New Products, Macular Degeneration, Paul Ryan, Drugs and Medicines

  18. Mar 17, 2013 |Story| Los Angeles Times
  19. Battle over 'biosimilars'

    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies what amounts to a 12-year monopoly on the substances they developed. Now, supporters of biologics are pushing lawmakers in Sacramento and other state capitals to put new hurdles in the way of knock-off compounds, called "biosimilars."
    One of the most promising frontiers in healthcare is biologic medicines — complex substances derived from living cells that can help fight chronic diseases and cancers. To encourage investment in biologics, Congress in 2010 gave drug companies...

    Tags: Food and Drug Administration, Justice System, Biotechnology, Crime, Law and Justice, Biotechnology Industry

  20. Mar 6, 2013 |Story| Los Angeles Times
  21. Facebook is about to redesign News Feed: Here's what to expect

    SAN FRANCISCO -- Facebook is rolling out a radical new redesign of News Feed, the biggest since it launched the feature in 2006.
    SAN FRANCISCO -- Facebook is rolling out a radical new redesign of News Feed, the biggest since it launched the feature in 2006. The giant social network plans to unveil the redesign at a press conference Thursday at its Menlo Park, Calif.,...

    Tags: George Takei, Corporate Officers, Mark Cuban, Media Industry, Biotechnology

  22. Mar 3, 2013 |Story| Baltimore Sun
  23. Asthma drug calms chronic hives, rashes

    Sufferers of chronic hives and rashes could benefit from a commonly-used asthma drug, Johns Hopkins researchers have found. Scientists found that a once-a-month dose of the drug omalizumab helped ease symptoms that standard antihistamines didn't....

    Tags: Asthma, Skin Rash, Medical Research, Symptoms, Novartis AG

 1  2 3 4 5 6Next >
Original site for Genentech Inc. topic gallery.
Advertisement
Loading...
 
 

Date:

Credit:

User-submitted

Tags:

Rate:
Sending...

E-mail this photo

Error: malformed email address(es)
Both "from" and "recipient" email fields are required.

Recipient E-mail Addresses

(up to 3, separated by commas) Send me a copy.

From:

e-mail | buy this photo | link to photo
Genentech Inc. Photos
Some firms seek to make "biosimilar" drugs that would p...
(April 25, 2013)
Bill would regulate ‘biosimilar’ drugs
A sign is displayed in front of the Genentech headquart...
(December 13, 2012)
A sign is displayed in front of the Genentech headquarters July 14, 2008 in South San Francisco, California. This company relied on the popularity of its cancer drug Avastin to boost profits.
Dr. Jeffrey Bloss has joined Astellas US LLC as vice pr...
(November 28, 2012)
Dr. Jeffrey Bloss, vice president of scientific and medical affairs, Astellas US LLC